-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S. Distribution Agreement with California-based Mycrodose Therapeutics Inc., a leading pharmaceutical company specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III substances and other compounds aimed at treating cancer-related conditions, mental health, and cognitive degenerative diseases.
The agreement will facilitate the import of HAVN Life's naturally derived GMP psilocybin to research institutions and researchers within the U.S. "at competitive prices" to alleviate "supply chain issues," reported HAVN in a press release.
"HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics," said HAVN Life CEO, Tim Moore. "We've been working closely with Chad and his team, and are excited about the potential of this partnership."
In December 2021, Mycrodose added a Schedule I Import license, which allows the import of psilocybin and psilocin for clinical trials, research and development, analytical purposes and distribution.
"Our company's proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose's ability to lead the U.S.-Pharmaceutical sector," stated Chad Conner, CEO of Mycrodose Therapeutics. "This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company."
According to HVN, "the interest and demand for psilocybin research in the United States have grown significantly in 2021 and continue to outpace supply in 2022."
The firm noted that the DEA Increased the quota for psilocybin research in the U.S. Meanwhile HAVN and Mycrodose, have completed the first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States.
Image By Ilona Szentivanyi.
HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S. Distribution Agreement with California-based Mycrodose Therapeutics Inc., a leading pharmaceutical company specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III substances and other compounds aimed at treating cancer-related conditions, mental health, and cognitive degenerative diseases.
HAVN生命科学公司。(CSE:HAVN)(场外交易代码:HAVLF)(FSE:5NP)是一家生物技术公司,致力于研究迷幻化合物以支持大脑健康和认知功能,该公司周四宣布与总部位于加利福尼亚州的公司签订独家美国分销协议麦克罗剂量治疗公司。是一家领先的制药公司,专门研究和开发先进的药物输送系统,利用DEA附表I、II和III物质和其他化合物,旨在治疗癌症相关疾病、精神健康和认知退行性疾病。
The agreement will facilitate the import of HAVN Life's naturally derived GMP psilocybin to research institutions and researchers within the U.S. "at competitive prices" to alleviate "supply chain issues," reported HAVN in a press release.
HAVN在一份新闻稿中报道,这项协议将促进HAVN Life天然提取的GMP裸盖菇素“以具有竞争力的价格”进口到美国境内的研究机构和研究人员,以缓解“供应链问题”。
"HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics," said HAVN Life CEO, Tim Moore. "We've been working closely with Chad and his team, and are excited about the potential of this partnership."
HAVN Life首席执行官说:“2022年伊始,HAVN Life在我们的研究和零售部门都建立了强有力的合作伙伴关系,我们非常高兴能与我们新的美国分销合作伙伴Mycroose Treeutics一起为我们的研究客户完成采购订单,”HAVN Life首席执行官说:“HAVN Life在我们的研究和零售部门都有强大的合作伙伴关系。蒂姆·摩尔。“我们一直在与乍得和他的团队密切合作,并对这种伙伴关系的潜力感到兴奋。”
In December 2021, Mycrodose added a Schedule I Import license, which allows the import of psilocybin and psilocin for clinical trials, research and development, analytical purposes and distribution.
2021年12月,麦克罗糖增加了附表一进口许可证,允许进口裸盖菇素和裸盖菇素用于临床试验、研发、分析目的和分销。
"Our company's proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose's ability to lead the U.S.-Pharmaceutical sector," stated Chad Conner, CEO of Mycrodose Therapeutics. "This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company."
他说:“我们公司被证明有能力驾驭DEA和FDA批准这些非常困难的许可证所需的细致细节,这直接促成了麦克罗糖领导美国制药行业的能力。”查德·康纳麦克罗剂量治疗公司的首席执行官。与HAVN Life的这一经销伙伴关系增加了任何总部设在美国的研究机构、大学或私营生物技术公司获得GMP裸盖菇素的机会和便利性。“
According to HVN, "the interest and demand for psilocybin research in the United States have grown significantly in 2021 and continue to outpace supply in 2022."
据HVN报道,“美国对裸盖菇素研究的兴趣和需求在2021年大幅增长,并在2022年继续超过供应。”
The firm noted that the DEA Increased the quota for psilocybin research in the U.S. Meanwhile HAVN and Mycrodose, have completed the first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States.
该公司指出,DEA增加了美国裸盖菇素研究的配额。与此同时,HAVN和Mycrodde已经完成了从牙买加向美国运送天然GMP生裸盖菌素蘑菇的第一笔订单和交货。
Image By Ilona Szentivanyi.
图片由Ilona Szentivanyi拍摄。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧